🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Zenta Walther

Yale University

ORCID: 0000-0003-2878-361X
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.104Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188
Top 78%
0.104DataRank
Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Papers

Driven by 12 papers — median percentile 22. Top paper: “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors”.

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7
N/A
0.769DataRank · unranked
168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.10.001
N/A
0.617DataRank · unranked
60 citations

Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu +11 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741
N/A
0.606DataRank · unranked
56 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Nature Communications(2022)10.1038/s41467-022-34398-z
N/A
0.584DataRank · unranked
48 citations

David Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther +6 more

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3497
N/A
0.564DataRank · unranked
42 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz +16 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532
N/A
0.552DataRank · unranked
9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Cancer Research(2024)10.1158/0008-5472.can-23-0438
N/A
0.489DataRank · unranked
25 citations

Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu, Lok-Hei Chan, Jungmin Choi +15 more

Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9104
N/A
0.104DataRank · unranked
1 citations

Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu +7 more

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188
Top 78%
0.104DataRank
Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21112
N/A
0DataRank · unranked
0 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Anna Wurtz, Zofia Piotrowska, Andrew J. Piper‐Vallillo +13 more

A PDZ-Binding Motif Controls Basolateral Targeting of Syndecan-1 Along the Biosynthetic Pathway in Polarized Epithelial Cells

UNC Libraries(2020)10.17615/stpz-j523
N/A
0DataRank · unranked
0 citations

Heike Fölsch, James M. Anderson, Jeff Sfakianos, Zenta Walther, Eric Anderson +5 more

A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition

npj Precision Oncology(2024)10.1038/s41698-023-00490-w
N/A
0DataRank · unranked
4 citations

Zaritza O. Petrova, Lisa Hunihan, Kumar Dilip Ashtekar, Zenta Walther, Frederick H. Wilson +1 more